Sodium Oligomannate for Alzheimer's Disease

An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

Recruiting Phase 4 Interventional Study
Alzheimer's Disease
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
50 – 85
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
1,312 (estimated)
Sponsor
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. · Industry
Who this trial is looking for

This trial is looking for people with mild to moderate Alzheimer's disease to see if sodium oligomannate is effective and safe for long-term use. Participants will need to meet specific health criteria and will be monitored for any side effects during the study.

Are You a Good Fit for This Trial?
Must not be taking DonepezilRivastigmineGalanthamineHuperzine AMemantineAducanumab

You may be able to join if

  • I have mild to moderate Alzheimer's disease.
  • I have had a decline in cognitive and functional abilities for at least 1 year.
  • My test score is between 11 and 24.
  • My Hachinski Ischemic Score is 4 or less.
  • My depression rating score is 10 or less.
  • I have an MRI that supports an Alzheimer's diagnosis.
  • I have a reliable study partner or caregiver.
  • I can sign the informed consent form.

You may not be able to join if

  • I have a different type of dementia.
  • I have major brain disease shown in an MRI.
  • My resting heart rate is less than 50 beats per minute.
  • I have had a major medical illness or unstable condition in the past year.
  • I have taken certain Alzheimer's medications in the last 6 months.
  • I have inadequate liver function.
  • I have inadequate organ function.
  • My ECG shows significant abnormalities.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The primary purpose of this study is to confirm the clinical efficacy and mechanism of action of GV-971, and identify incidence of known adverse reactions in long-term use and observe new adverse reactions, providing more guidance for clinical use.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Mild to moderate AD per NIA-AA. * History of cognitive and functional decline over at least 1 year. * MMSE scores between 11 and 24 (inclusive) at baseline. * Hachinski Ischemic Score (HIS) scale total score ≤ 4. * Hamilton Rating Scale for Depression/17 items (HAMD) total sco…
Contacts

Medical Director, Ph. D

+86 21 50504988

xinxianliang@greenvalleypharma.com

CONTACT